



**aimovig**<sup>®</sup>  
erenumab

Neuroscience

**AIMOVIG<sup>®</sup> (erenumab)**

[Prescribing information](#)



**Kesimpta**<sup>®</sup> ▼  
**ofatumumab**

Neuroscience

**KESIMPTA<sup>®</sup> ▼ (ofatumumab)**

[Prescribing information](#)



**MAYZENT**<sup>®</sup> ▼  
**siponimod**

Neuroscience

**MAYZENT®▼ (siponimod)**

[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/medicines/neuroscience>